"Immunoconjugates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
| Descriptor ID |
D018796
|
| MeSH Number(s) |
D12.776.124.790.651.114.580 D12.776.377.715.548.114.580
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunoconjugates".
Below are MeSH descriptors whose meaning is more specific than "Immunoconjugates".
This graph shows the total number of publications written about "Immunoconjugates" by people in this website by year, and whether "Immunoconjugates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 0 | 5 |
| 1997 | 6 | 0 | 6 |
| 1998 | 6 | 0 | 6 |
| 1999 | 7 | 0 | 7 |
| 2000 | 7 | 0 | 7 |
| 2001 | 10 | 0 | 10 |
| 2002 | 6 | 0 | 6 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 2 | 3 |
| 2006 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 2 | 3 |
| 2019 | 4 | 0 | 4 |
| 2020 | 7 | 1 | 8 |
| 2021 | 3 | 0 | 3 |
| 2022 | 6 | 0 | 6 |
| 2023 | 3 | 1 | 4 |
| 2024 | 6 | 4 | 10 |
| 2025 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunoconjugates" by people in Profiles.
-
Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma. JAMA Ophthalmol. 2025 06 01; 143(6):507-514.
-
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor a-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr; 26(4):503-515.
-
Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics. Gynecol Oncol. 2025 Apr; 195:180-191.
-
Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates. Future Oncol. 2025 Apr; 21(10):1261-1272.
-
Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma. Clin Lung Cancer. 2025 May; 26(3):165-167.
-
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer. Clin Cancer Res. 2024 Nov 15; 30(22):5042-5052.
-
Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies. Oncologist. 2024 Nov 04; 29(11):e1435-e1451.
-
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. J Clin Oncol. 2025 Jan 10; 43(2):201-213.
-
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.